IRVINE, Calif., Jan. 12, 2021 /PRNewswire/ -- Today Allergan
Aesthetics, an AbbVie company (NYSE: ABBV), announced that it has
entered into a warrant agreement with Cypris Medical, a privately
held, medical device company based in Chicago. Following the completion of a
clinical trial to be initiated in 2021, Allergan Aesthetics will
have the right to exercise an option to acquire Cypris Medical,
including the company's Xact device. The planned clinical trial
will evaluate the safety and effectiveness of Xact in treating
midface descent as well as for neck lifts.
Replacing the scalpel, Xact is designed to allow for lifting and
suturing of the superficial muscular aponeurotic system (SMAS), the
same tissue mobilized in a facelift, but in a minimally-invasive
manner. The innovative technology intends to provide patients
surgery-like results in the office with little to no downtime.
"As a global leader in aesthetics, we are proud to support the
research of an innovative device that complements our iconic
portfolio of non-invasive treatment options like Botox Cosmetic and
our Juvéderm Collection of Fillers," says Carrie Strom, SVP AbbVie and President, Global
Allergan Aesthetics. "We know there is continued unmet need for
minimally-invasive procedures for midface descent, and Xact affords
us the ability to create a new alternative for our customers so
they can continue to offer leading-edge treatments to patients."
"As the market leader in facial aesthetics, Allergan Aesthetics
is the ideal partner to lead the advancement and continued
development of Xact," says Dan
Holton, President and CEO, Cypris Medical. "We share the
same vision with respect to product safety, efficacy and
data-driven innovation which allow us to offer plastic surgeons and
patients new options for aesthetic medicine."
About Allergan Aesthetics
At Allergan Aesthetics, an AbbVie company, we develop,
manufacture, and market a portfolio of leading aesthetics brands
and products. Our aesthetics portfolio includes facial injectables,
body contouring, plastics, skin care, and more. Our goal is to
consistently provide our customers with innovation, education,
exceptional service, and a commitment to excellence, all with a
personal touch. For more information,
visit www.AllerganAesthetics.com.
About AbbVie
AbbVie's mission is to discover and deliver innovative medicines
that solve serious health issues today and address the medical
challenges of tomorrow. We strive to have a remarkable impact on
people's lives across several key therapeutic areas: immunology,
oncology, neuroscience, eye care, virology, women's health and
gastroenterology, in addition to products and services across its
Allergan Aesthetics portfolio. For more information about AbbVie,
please visit us at www.abbvie.com.
Follow @abbvie on Twitter, Facebook, Instagram, YouTube and LinkedIn.
Forward-Looking Statements
Some statements in this news release are, or may be
considered, forward-looking statements for purposes of the Private
Securities Litigation Reform Act of 1995. The words "believe,"
"expect," "anticipate," "project" and similar expressions, among
others, generally identify forward-looking statements. AbbVie
cautions that these forward-looking statements are subject to risks
and uncertainties that may cause actual results to differ
materially from those indicated in the forward-looking statements.
Such risks and uncertainties include, but are not limited to,
failure to realize the expected benefits from AbbVie's acquisition
of Allergan plc ("Allergan"), failure to promptly and effectively
integrate Allergan's businesses, competition from other products,
challenges to intellectual property, difficulties inherent in the
research and development process, adverse litigation or government
action, changes to laws and regulations applicable to our industry
and the impact of public health outbreaks, epidemics or pandemics,
such as COVID-19. Additional information about the economic,
competitive, governmental, technological and other factors that may
affect AbbVie's operations is set forth in Item 1A, "Risk Factors,"
of AbbVie's 2019 Annual Report on Form 10-K, which has been filed
with the Securities and Exchange Commission, as updated by its
subsequent Quarterly Reports on Form 10-Q. AbbVie undertakes no
obligation to release publicly any revisions to forward-looking
statements as a result of subsequent events or developments, except
as required by law.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/allergan-aesthetics-enters-into-option-to-acquire-cypris-medical-301206886.html
SOURCE AbbVie